KDR and neoplasm: An investigational report suggested that tumor progression during anti-VEGF therapies is associated with upregulation of ANG/TIE2 and dual blockade of VEGF/VEGFR and ANG/TIE2 could restore drug sensitivity in tumor cells resistant to anti-VEGF therapy [205].